Incyte (INCY) Other Non-Current Assets (2010 - 2026)
Incyte's (INCY) quarterly Other Non-Current Assets came in at $86.8 million in Q2 2026, up 166.52% YoY from $32.6 million in Q2 2025, and up 254.23% on a QoQ basis from $24.5 million in Q1 2026.
Incyte (INCY) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Incyte (INCY) has 16 years of Other Non-Current Assets data on file, last reported at $86.8 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 166.52% year-over-year to $86.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $86.8 million (up 166.52% YoY) and the FY2025 annual result came in at $18.2 million, up 67.46% from the prior year.
- Other Non-Current Assets rose to $86.8 million in Q2 2026, from $24.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $86.8 million in Q2 2026 to a low of $10.8 million in Q4 2024.
- A 5-year average of $35.2 million and a median of $30.8 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 242.07% — and 2024, when it plunged 79.18%.
- Tracing INCY's Other Non-Current Assets over 5 years: stood at $25.4 million in 2022, then surged by 104.86% to $52.1 million in 2023, then sank by 79.18% to $10.8 million in 2024, then soared by 67.46% to $18.2 million in 2025, then jumped by 377.59% to $86.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $86.8 million (Q2 2026), $24.5 million (Q1 2026), and $18.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 86.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.76 Mn |
| Mar 31, 2026 | 24.49 Mn |
| Dec 31, 2025 | 18.17 Mn |
| Sep 30, 2025 | 32.30 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 30.15 Mn |
| Dec 31, 2024 | 10.85 Mn |
| Sep 30, 2024 | 40.38 Mn |
| Jun 30, 2024 | 21.92 Mn |
| Mar 31, 2024 | 47.40 Mn |
| Dec 31, 2023 | 52.11 Mn |
| Sep 30, 2023 | 80.96 Mn |
| Jun 30, 2023 | 31.71 Mn |
| Mar 31, 2023 | 20.72 Mn |
| Dec 31, 2022 | 25.44 Mn |
| Sep 30, 2022 | 23.67 Mn |
| Jun 30, 2022 | 23.01 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 24.79 Mn |